-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals reading only
to see what was said at the ASTRO conference!
of patients with early-stage breast cancer who are at high risk of recurrence.
Research screenshots
for patients at higher risk of tumor recurrence.
Frank a.
Vicini, MD, radiation oncologist, director of research at GenesisCare, principal investigator of FASTRO, said
with early-stage breast cancer who were at high risk of local recurrence after lumpectomy.
Risk factors include tumor grade, age, whether to receive preoperative chemotherapy and estrogen receptor status
.
The median age of the patients was 55 years, and patients were treated
at 276 different sites in the United States, Canada, Switzerland, Israel, Hong Kong, Japan, South Korea and Singapore.
In this study, patients were randomly divided into two study groups
.
Group A patients (n=1124) received routine total breast radiation therapy for 4 to 5 weeks, followed by continuous increased treatment
at the tumor resection site within 6 to 7 days.
Group B patients (n=1138) received hypofractionated whole-breast radiotherapy for three weeks, while the surgical site was given increased radiotherapy
during these three weeks.
At a median follow-up of 7.
3 years, there were 56 cases of intramammary recurrence
among nearly 2300 study participants.
Regarding breast tumor recurrence, the primary endpoint of the study, group B was no lower than group A (HR: 1.
32, 90% CI: 0.
84 to 2.
05, p=0.
039).
The 5-year and 7-year recurrence rates were 1.
9% and 2.
6% in group B, and 2.
0% and 2.
2%
in group A, respectively.
There were also no significant differences
between the two groups in terms of appearance or side effects.
At 3 years after treatment, 86% and 84% of patients in groups A and B, respectively, had their appearance rated as excellent or good
by their doctors.
Severe (grade ≥ 3) side effects were uncommon in both groups, 3.
3% in group A and 3.
5%
in group B.
Frank a.
Vicini, MD, radiation oncologist, director of research at GenesisCare, principal investigator of FASTRO, said:
further.
For example, a study in the United Kingdom is giving a week of radiotherapy
to patients at low risk of recurrence.
to see what was said at the ASTRO conference!
Executive summary
of patients with early-stage breast cancer who are at high risk of recurrence.
Research screenshots
status quo
for patients at higher risk of tumor recurrence.
Frank a.
Vicini, MD, radiation oncologist, director of research at GenesisCare, principal investigator of FASTRO, said
- Supplemental radiation therapy can reduce the likelihood of breast tumour recurrence by 20% to 30%, but adding this increased dose of radiotherapy after hypofractionated radiotherapy increases the duration
of treatment by one week.
This is a challenge
for patients who need to take time off or travel long distances for treatment. - The trial wanted to investigate whether this increased dose of radiotherapy could be equally effective in delivering efficacy while shortening the treatment process, without increasing side effects or affecting breast appearance
.
conclusion
with early-stage breast cancer who were at high risk of local recurrence after lumpectomy.
Risk factors include tumor grade, age, whether to receive preoperative chemotherapy and estrogen receptor status
.
The median age of the patients was 55 years, and patients were treated
at 276 different sites in the United States, Canada, Switzerland, Israel, Hong Kong, Japan, South Korea and Singapore.
In this study, patients were randomly divided into two study groups
.
Group A patients (n=1124) received routine total breast radiation therapy for 4 to 5 weeks, followed by continuous increased treatment
at the tumor resection site within 6 to 7 days.
Group B patients (n=1138) received hypofractionated whole-breast radiotherapy for three weeks, while the surgical site was given increased radiotherapy
during these three weeks.
At a median follow-up of 7.
3 years, there were 56 cases of intramammary recurrence
among nearly 2300 study participants.
Regarding breast tumor recurrence, the primary endpoint of the study, group B was no lower than group A (HR: 1.
32, 90% CI: 0.
84 to 2.
05, p=0.
039).
The 5-year and 7-year recurrence rates were 1.
9% and 2.
6% in group B, and 2.
0% and 2.
2%
in group A, respectively.
There were also no significant differences
between the two groups in terms of appearance or side effects.
At 3 years after treatment, 86% and 84% of patients in groups A and B, respectively, had their appearance rated as excellent or good
by their doctors.
Severe (grade ≥ 3) side effects were uncommon in both groups, 3.
3% in group A and 3.
5%
in group B.
prospect
Frank a.
Vicini, MD, radiation oncologist, director of research at GenesisCare, principal investigator of FASTRO, said:
- This approach cuts the treatment time of these patients in half and is suitable for patients at
high risk of recurrence. - In-depth knowledge of breast cancer therapies and advances in treatment techniques may be behind
the low recurrence rates and side effects.
Over the years, surgery, pathology reports, radiotherapy, chemotherapy – these things have been constantly improving
.
We can administer it
in a more complex way.
As a result, the recurrence rate is decreasing, while the success rate of treatment is rising
.
”
further.
For example, a study in the United Kingdom is giving a week of radiotherapy
to patients at low risk of recurrence.
Commentary first published: Medical press
Written by the American Society for Radiation Oncology
Click "Read Original" to get more clinical dry goods
